

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): An immunogenic composition comprising,
(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, ~~and immunogenic fragments of said immunogenic peptide wherein said peptide fragment does not consist of SEQ ID NO:2;~~ and
(b) a pharmaceutically acceptable carrier.

wd/scope
to SID
'

Claim 6 (currently amended): The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide consists of ~~SEQ ID NOS: 1 or 2~~
SEQ ID NO: 1.

Claim 7 (previously presented): The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 8 (original): The composition of Claim 7, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 9 (original): The composition of Claim 7, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 10 (original): The composition of Claim 9, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

Claim 11 (previously presented): The composition of Claim 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

Claim 12 (original): The composition of Claim 11, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

Claim 13 (original): The composition of Claim 11, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

Claim 14 (canceled)

Claim 15 (currently amended): An immunogenic composition comprising,
(a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide factor;

- (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9; and
- (c) a pharmaceutically acceptable carrier.

Claim 16 (canceled)

Claim 17 (previously presented): The composition of Claim 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 18 (original): The composition of Claim 17, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 19 (original): The composition of Claim 17, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 20 (original): The composition of Claim 19, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

Claim 21 (previously presented): The composition of Claim 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

Claim 22 (original): The composition of Claim 21, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

Claim 23 (original): The composition of Claim 21, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

Claim 24 (canceled)

Claim 25 (currently amended) An immunogenic composition comprising,
(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of a heparin binding domain and ~~immunogenic fragments of said immunogenic peptide, and~~ wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of a receptor binding domain and ~~immunogenic fragments of said immunogenic peptide;~~ and
(b) a pharmaceutically acceptable carrier.

Claim 26 (previously presented) The composition of Claim 25, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 27 (original): The composition of Claim 26, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 28 (original): The composition of Claim 26, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 29 (original): The composition of Claim 28, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

Claim 30 (withdrawn): A method for treating cancer or hyperproliferative disorders in a human or animal comprising administering to the human or animal an effective amount of a composition comprising an immunogenic peptide fragment of fibroblast growth factor and a pharmaceutically acceptable carrier.

Claim 31 (withdrawn): The method of Claim 30, wherein the immunogenic peptide fragment corresponds to the heparin binding domain of fibroblast growth factor.

Claim 32 (withdrawn): The method of Claim 30, wherein the amino acid sequence of the immunogenic peptide fragment comprises SEQ ID NOS: 1 and 2.

Claim 33 (withdrawn): The method of Claim 30, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 34 (withdrawn): The method of Claim 30, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 35 (withdrawn): The method of Claim 30, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 36 (withdrawn): The method of Claim 30, wherein the hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, placentation, and cat scratch fever.

Claim 37 (withdrawn): A method for treating cancer or hyperproliferative disorders in a human or animal comprising administering to the human or animal an effective amount of a composition comprising an immunogenic peptide fragment of vascular endothelial growth factor and a pharmaceutically acceptable carrier.

Claim 38 (withdrawn): The method of Claim 37, wherein the immunogenic peptide fragment corresponds to the receptor binding domain of vascular endothelial growth factor.

Claim 39 (withdrawn): The method of Claim 37, wherein the amino acid sequence of the immunogenic peptide fragment comprises SEQ ID NOS: 3-9.

Claim 40 (withdrawn): The method of Claim 37, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 41 (withdrawn): The method of Claim 37, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin,

ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 42 (withdrawn): The method of Claim 37, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 43 (withdrawn): The method of Claim 37, wherein the hyperproliferative disorder comprises hemangioma, solid tumors, blood borne tumors, leukemia, metastasis, telangiectasia, psoriasis, scleroderma, pyogenic granuloma, myocardial angiogenesis, Crohn's disease, plaque neovascularization, arteriovenous malformations, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, Helicobacter related diseases, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, placentation, and cat scratch fever.

Claim 44 (withdrawn): A method of treating a human or animal in need of an immune response to a growth factor comprising administering to a human or animal an effective amount of a growth factor composition, wherein the composition comprises,

- (a) an immunogenic peptide fragment of fibroblast growth factor; and
- (b) a pharmaceutically acceptable carrier such that the composition is immunogenic for fibroblast growth factor when administered to a human or animal.

Claim 45 (withdrawn): The method of Claim 44, wherein the immunogenic peptide comprises SEQ ID NOS: 1 and 2.

Claim 46 (withdrawn): The method of Claim 44, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 47 (withdrawn): A method of treating a human or animal in need of an immune response to a growth factor comprising administering to a human or animal an effective amount of a growth factor composition, wherein the composition comprises,

- (a) an immunogenic peptide fragment of vascular endothelial growth factor; and
- (b) a pharmaceutically acceptable carrier such that the composition is immunogenic for vascular endothelial growth factor when administered to a human or animal.

Claim 48 (withdrawn): The method of Claim 47, wherein the immunogenic peptide comprises SEQ ID NOS: 3-9.

Claim 49 (withdrawn): The method of Claim 47, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 50 (original): An immunogenic composition comprising,

- (a) An immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide
- (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 6; and
- (c) a pharmaceutically acceptable carrier.